HIGHLIGHTS
- Who: Th et al. from the (CSIC), Spain School of Life Sciences, Pharmacy and Chemistry, Kingston University London, London, United Kingdom have published the article: Missed opportunities to increase ef fi ciency of monoclonal antibody development using hybridoma technology and mice as the source animal, in the Journal: (JOURNAL)
SUMMARY
A tumor antigen must be sufficiently immunogenic to induce antibody production, and immunogenicity is determined by the strength of presentation by major histocompatibility complex (MHC)-encoded histocompatibility antigens. Not each peptide has sufficiently strong affinity to each MHC antigen, and therefore antigen presentation . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.